Acacia Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12345678910111213...2223»
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Review, Journal:  Unexpected Pneumothorax During Painless Flexible Bronchoscopy Under Remimazolam Sedation: Two Case Reports and a Literature Review. (Pubmed Central) -  Nov 19, 2024   
    A sudden decrease in heart rate, combined with hypoxemia, is highly effective for detecting pneumothorax in patients undergoing PFB, with subcutaneous emphysema serving as a key auxiliary diagnostic sign. Remimazolam may provide significant clinical benefits in emergency situations during PFB by allowing patients to be quickly awakened to assist with diagnosis.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Case report of atypical re-sedation after general anesthesia using remimazolam. (Pubmed Central) -  Nov 15, 2024   
    This case challenges our understanding of remimazolam's dynamics, emphasizing the necessity for vigilant post-anesthesia monitoring, even in seemingly low-risk cases. It advocates for standardized response protocols to promptly manage unforeseen events and ensure patient safety.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Effect of remimazolam toluene sulfonate on the cognitive function of juveniles and its mechanism of action. (Pubmed Central) -  Nov 14, 2024   
    Concurrently, the extent of caspase-3 upregulation, the number of neuronal apoptosis in CA1 and CA3 regions, a downward trend of PSD95 and BDNF in the hippocampus, and the inhibition of LTP were highly consistent with the behavior of short-term memory impairment. These results indicate that the degree of memory impairment caused by remimazolam is milder than that caused by midazolam, making it a potential replacement for midazolam in repeated medication and long-term sedation in children.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Retrospective data, Journal, Surgery:  Retrospective Study on the Incidence of Postoperative Nausea and Vomiting and Hypotension During Orthognathic Surgery Using Propofol or Remimazolam. (Pubmed Central) -  Nov 6, 2024   
    These results suggest that propofol is associated with a lower incidence of early PONV as compared to remimazolam; however, antiemetics are still recommended given the frequency of late PONV in both groups. Propofol also caused more episodes of intraoperative hypotension vs remimazolam, but the increase in transient hypotension is likely to be irrelevant during orthognathic surgery in healthy adults under the age of 60.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    The Benefit of Introducing Remimazolam for Procedural Sedation in Belgian Clinical Practice () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2742;    
    While offering an environmentally valuable alternative to SoC, the potential for shorter procedures can result in optimized availability of the operating theatres and post-sedation care units. This can result in improved access to healthcare, generating savings for both the government and hospitals.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    The Benefit of Introducing Remimazolam for General Anesthesia in Belgian Clinical Practice () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2500;    
    Remimazolam is the first novel anesthetic in decades with the potential to optimize the organization of clinical practice in GA by reallocating scarce resources. While offering an environmentally valuable alternative to SoC, remimazolam can result in optimized access to healthcare, generating savings for both the government and hospitals.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical Practice. (Pubmed Central) -  Nov 1, 2024   
    DEX and RMZ possess several properties of an optimal sedative, including clinically insignificant main metabolites and a broad dosage range, indicating their potential to reduce the incidence of sedation-related life-threatening events in children. However, further clinical research is necessary to better evaluate their potential risks.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Trial completion date:  Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients (clinicaltrials.gov) -  Oct 31, 2024   
    P=N/A,  N=146, Completed, 
    Post-surgery levels of epinephrine (E), norepinephrine (NE), and cortisol (Cor) at 24 Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Enrollment change:  Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy (clinicaltrials.gov) -  Oct 30, 2024   
    P=N/A,  N=333, Completed, 
    Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024 Recruiting --> Completed | N=120 --> 333
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children (clinicaltrials.gov) -  Oct 28, 2024   
    P=N/A,  N=114, Completed, 
    Recruiting --> Completed | N=120 --> 333 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=165 --> 114 | Trial completion date: Dec 2024 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Apr 2024
  • ||||||||||  Penthrox (methoxyflurane) / Medical Developments International, ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Review, Journal:  The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review. (Pubmed Central) -  Oct 28, 2024   
    Ketamine, nitrous oxide, and xenon are not GABAR agonists and instead inhibit glutamate receptors-mainly NMDA receptors...Isoflurane and sevoflurane might have slightly different binding sites providing unexpected degree of selectivity...Penthrox (Galen, UK) is the special device designed for its administration...Remimazolam, a modified midazolam and methoxycarbonyl-etomidate (MOC-etomidate), an ultrashort-acting etomidate analog are two such examples...Carboetomidate is another soft analog of etomidate with low affinity for 11?-hydroxylase and is, therefore, unlikely to have clinically significant adrenocortical suppressant effects. Alphaxalone, a GABAAR agonist, is recently formulated in combination with 7-sulfobutylether-?-cyclodextrin (SBECD), which has a low hypersensitivity profile.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction. (Pubmed Central) -  Oct 27, 2024   
    Remimazolam demonstrated neuroprotective and anti-neuroinflammatory effects in a mouse model of LPS-induced cognitive impairment. These effects are likely mediated through the regulation of TSPO, which inhibits microglial activation and promotes the polarization of microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Intraoperative neuromonitoring of visual evoked potentials in a pregnant patient with meningioma: a case report. (Pubmed Central) -  Oct 26, 2024   
    Our experience with intraoperative neuromonitoring of a pregnant woman in the third trimester showed that anesthesia with remimazolam allows safe brain surgery combined with intraoperative visual evoked potential monitoring. Further research is needed to determine the effects of remimazolam on the fetus, as well as the safe dosage and duration of exposure.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  Remimazolam in Cardiac Anesthesia: Not So "Ultra-short Acting" After All. (Pubmed Central) -  Oct 26, 2024   
    Further research is needed to determine the effects of remimazolam on the fetus, as well as the safe dosage and duration of exposure. No abstract available
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    State of the Art Bronchoscopic Techniques for Diagnosis (CRYSTAL 3; 3F) -  Oct 21, 2024 - Abstract #KATRDIC2024KATRDIC_11;    
    P2
    Remimazolam is a recently developed ultra-short-acting benzodiazepine sedative...In particular, with the development of a 1.1 mm cryoprobe, it has become possible to perform cryobiopsy through a GS following conventional biopsies, such as forceps, aspiration needle, and brushing, when performing TBLB. Cryobiopsy increases the risk of bleeding; it is known to be relatively safe to perform by an experienced operator, even in high- bleeding-risk patients.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Preclinical, Journal:  Neonatal anesthesia with remimazolam Reduces the expression of synaptic proteins and increases depressive behavior in adult mice. (Pubmed Central) -  Oct 19, 2024   
    Acute reductions in synaptic protein expression post-anesthesia were observed, along with long-term decreases in hippocampal choline acetyltransferase levels, reduced dendritic spine density in the CA1 region, and microglial proliferation. Collectively, these findings suggest that remimazolam can induce neurotoxicity and neuroinflammation, leading to synaptic dysfunction and associated cognitive and behavioral deficits.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Journal:  The Emerging Role of Remimazolam in Cardiac Anesthesia: The Devil Is in the Details. (Pubmed Central) -  Oct 19, 2024   
    Collectively, these findings suggest that remimazolam can induce neurotoxicity and neuroinflammation, leading to synaptic dysfunction and associated cognitive and behavioral deficits. No abstract available
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, ciprofol injectable emulsion (HSK3486) / Haisco, Belsomra (suvorexant) / Merck (MSD)
    Review, Journal:  Postoperative Delirium and Neurocognitive Disorders: Updates for Providers Caring for Cancer Patients. (Pubmed Central) -  Oct 15, 2024   
    Studies investigating ciprofol, remimazolam, esketamine, ramelteon and suvorexant have shown encouraging results...Innovative approaches to address PND are a rapidly developing area of research, but more studies are needed to identify effective prevention and management interventions. Despite challenges and controversy in the field, implementation of best practice can reduce the detrimental impact of PND on patients, caregivers, and society at large.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Trial completion date, Trial primary completion date:  Impact of CES1 Genotype on Remimazolam (clinicaltrials.gov) -  Oct 15, 2024   
    P=N/A,  N=120, Recruiting, 
    Despite challenges and controversy in the field, implementation of best practice can reduce the detrimental impact of PND on patients, caregivers, and society at large. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
    Enrollment change, Surgery:  Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients (clinicaltrials.gov) -  Oct 15, 2024   
    P=N/A,  N=150, Not yet recruiting, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 N=100 --> 150